Planet 13 Holdings (PLNH) Cash from Financing Activities (2021 - 2025)
Planet 13 Holdings (PLNH) posted quarterly Cash from Financing Activities of $1.8 million for Q2 2025, up 150.55% year-over-year from $698465.9 in Q2 2024, and up 3241.74% quarter-over-quarter from $52368.0 in Q1 2025.
Planet 13 Holdings (PLNH) Cash from Financing Activities (2021 - 2025) Analysis & Trends
Planet 13 Holdings (PLNH) has reported Cash from Financing Activities for 5 consecutive years, with $1.8 million the latest figure, recorded in Q2 2025.
- In Q2 2025, Cash from Financing Activities rose 150.55% year-over-year to $1.8 million; the TTM figure through Mar 2026 stood at $1.8 million (up 155.85% YoY), while the FY2025 annual figure was $1.8 million, down 73.21% from the prior year.
- Cash from Financing Activities grew to $1.8 million in Q2 2025 per PLNH's latest filing, from $52368.0 in the prior quarter.
- Across five years, Cash from Financing Activities topped out at $61.2 million in Q1 2021 and bottomed at -$3.5 million in Q2 2024.
- Historically, Cash from Financing Activities has averaged $5.3 million across 5 years, with a median of $75174.0 in 2022.
- Annual changes were most pronounced in 2022 — Cash from Financing Activities surged 5929.2% — and 2024, when it tumbled 1527700.0%.
- Planet 13 Holdings' Cash from Financing Activities stood at $17320.0 in 2021, then soared by 5929.2% to $1.0 million in 2022, then tumbled by 100.0% to -$3.0 in 2023, then sank by 1527700.0% to -$45834.0 in 2024, then jumped by 3918.13% to $1.8 million in 2025.
- Business Quant data shows PLNH's Cash from Financing Activities at $1.8 million in Q2 2025, $52368.0 in Q1 2025, and -$45834.0 in Q4 2024.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Financing Activities (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 43.98 Bn | 43.02 Bn | - | - |
| 2 | Teva Pharmaceutical Industries | 43.28 Bn | 39.62 Bn | 2.15 Bn | -1.00 Mn |
| 3 | Zoetis | 31.78 Bn | 30.11 Bn | 1.05 Bn | -813.00 Mn |
| 4 | Takeda Pharmaceutical | 28.71 Bn | 22.91 Bn | 5.10 Bn | -1.13 Bn |
| 5 | United Therapeutics | 22.25 Bn | 19.59 Bn | 683.80 Mn | 122.40 Mn |
| 6 | Viatris | 18.72 Bn | 17.83 Bn | 1.46 Bn | -1.24 Bn |
| 7 | Neurocrine Biosciences | 15.57 Bn | 15.18 Bn | 935.80 Mn | 63.40 Mn |
| 8 | Elanco Animal Health | 11.87 Bn | 11.34 Bn | 798.00 Mn | -74.00 Mn |
| 9 | Dr Reddys Laboratories | 10.14 Bn | 9.97 Bn | - | - |
| 10 | Planet 13 Holdings | 47.95 Mn | 31.46 Mn | 12.32 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2025 | 1.75 Mn |
| Jun 30, 2025 | 1.75 Mn |
| Mar 31, 2025 | 52,368.00 |
| Mar 31, 2025 | 52,368.00 |
| Dec 31, 2024 | -45,834.00 |
| Dec 31, 2024 | -45,834.00 |
| Sep 30, 2024 | 322,049.00 |
| Sep 30, 2024 | 322,049.00 |
| Jun 30, 2024 | -3.46 Mn |
| Jun 30, 2024 | -3.46 Mn |
| Mar 31, 2024 | 9.91 Mn |
| Mar 31, 2024 | 9.91 Mn |
| Dec 31, 2023 | -3.00 |
| Dec 31, 2023 | -3.00 |
| Jun 30, 2023 | -267,526.00 |
| Jun 30, 2023 | -267,526.00 |
| Dec 31, 2022 | 1.04 Mn |
| Dec 31, 2022 | 1.04 Mn |
| Jun 30, 2022 | 97,980.00 |
| Jun 30, 2022 | 97,980.00 |